Medical/Pharmaceuticals
Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency
SAN DIEGO, May 29, 2023 /PRNewswire/ -- Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular junction disorders announced the award of a Fast Track Phase I/II STTR grant from theNIH-NINDS. This highly competitive gra...
2023-06-01 04:24
5903
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, May 31, 2023 /PRNewswire/ -- Actin...
2023-05-31 20:58
3327
QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION
BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited ( QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce thatRichard Godfrey will present to potential partners and investors at t...
2023-05-31 19:00
3829
Asieris' progress in MIBC receives renewed attention with its inclusion in ASCO 2023
SHANGHAI, May 31, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176)， a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the phase I clinical data of ANTICIPATE ...
2023-05-31 16:00
2661
Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC
SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO,Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'. The total contract size is325 million dollar...
2023-05-31 13:02
2178
Ascentage Pharma's Novel Drug Olverembatinib Recommended for a Breakthrough Therapy Designation in China for the Treatment of SDH-Deficient GIST, the Second BTD for the Drug
SUZHOU, China and ROCKVILLE, Md., May 30, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announcedtoday that the Center for Drug Evaluation (CDE) of China Na...
2023-05-31 10:20
2642
Lunit and the Japan National Cancer Center Hospital East Partner in AI Pathology to Advance Precision Oncology
* Collaborative research with Japan's largest oncology practice shows Lunit SCOPE's potential in predicting clinical outcomes for rectal cancer SEOUL, South Korea, May 30, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer diagnostic solutions, today announced c...
2023-05-30 20:00
3115
Inmagene to Participate in the Jefferies Healthcare Conference on June 8
SAN DIEGO, SHANGHAI and SYDNEY, May 30, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases, today announced that management has been invited to participate in the ...
2023-05-30 20:00
3075
Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first subject has been dosed in the Company's First-In-Human (FIH) Phase 1 multi-center st...
2023-05-30 19:00
2990
iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome
* It was confirmed the presence of Prophage and Jamphage in the Alkalihalobacillus clausii * Prophage and Jamphage are expected to play a substantial role in bacterial survival and immune regulation in the body. BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ...
2023-05-30 10:15
2739
Bridge Biotherapeutics to Present at the 2023 BIO International Convention
SEONGNAM, South Korea and CAMBRIDGE, Mass., May 29, 2023 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation onTuesday, June...
2023-05-30 06:00
3123
CELL WORLD - Aiming at Internationalization, Starting from Regulation - The 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration Successfully Held
SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou. The...
2023-05-29 20:03
4029
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer * FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US,Canada and most European countries * T...
2023-05-29 16:51
4240
Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models
OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating ant...
2023-05-29 13:21
2877
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023
* Porustobart in combination of toripalimab showed promising anti-tumor activity * Porustobart in combination of toripalimab showed acceptable safety profile in HCC * Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZH...
2023-05-29 09:42
3017
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT"), will be rele...
2023-05-28 21:00
4560
Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system
SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation. Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosi...
2023-05-26 22:08
4618
ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic
* PRO1160 first patient dosed in the US * China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials * Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage...
2023-05-26 20:00
3446
FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health
Supporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, aNew York-based strategic and financial advisory firm specializi...
2023-05-26 13:42
3068
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference
SUZHOU, China, and ROCKVILLE, Md., May 25, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presenta...
2023-05-26 10:01
3899
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
9361
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
8702
